Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05017272 · ClinicalTrials.gov registry record · NA

Technology for MAT in Primary Care - Phase 2

A NA study of Opioid Use Disorder, sponsored by Q2i.

Completed
Registry status
NA
Development phase
246
Enrollment target
1
Study location

NCT05017272 is a NA study of Opioid Use Disorder that has completed, run by Q2i. The registered enrollment target is 246 participants, below the 4,655-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05017272, a NA study of Opioid Use Disorder, has completed, sponsored by Q2i.

COMPLETED
Registry status
NA
Development phase
246 participants
Enrollment target
1
Study location

Study Summary

With over 72,000 overdose deaths in 2017, of which 47,600 are attributable to opioid overdose, the opioid epidemic has become North America's most widespread behavioral public health problem. Medication-assisted treatment (MAT) for opioid use disorder (OUD) is highly efficacious. The Opioid Addiction Recovery Support (OARS), comprised of a healthcare team portal connected to a patient mobile application, provides opioid-related education, promotes connectedness with clinicians, and tracks MAT treatment progress. This study will conduct interviews with patients that will inform optimal design of OARS, assess the efficacy of OARS in improving MAT outcomes in primary care settings, and evaluate the sustainability and return on investment. It joins an outstanding scientific team at University of California, Los Angeles and a small business that has developed, Opioid Addiction Recovery Support (OARS) -- a software platform that by integrating with the Electronic Health Record (EHR) improves clinical management of patients by primary care providers (PCPs) treating patients with OUD using MAT. OARS platform uses a dashboard to show the real-time measurement of patient achievements in recovery. It provides opportunities for patients to interact with their PCPs, allowing for better connection to and support from their PCPs. OARS platform features artificial intelligence to analyze information from the EHR and from patients to provide a relapse risk assessment for patients receiving MAT for OUD, an innovation that sets OARS apart from other software solutions. The goal of Phase 1 was to modify the OARS platform for use in primary care settings by conducting interviews with Primary Care Physicians (PCPs) (N=20) and their patients with OUD (N=40) in primary care settings to collect data on feasibility and acceptability of engaging with OARS to inform the user-centered design of OARS. The goals of Phase 2 of this study are to: (1) to assess the effectiveness of OARS in improvi

Conditions Studied

Interventions

  • OTHER Opioid Addiction Recovery Support Software Platform

Study Locations (1)

California

  • UCLA Center for Behavioral and Addiction Medicine - Los Angeles

Trial Details

FieldValue
Enrollment Target 246 participants
Start Date 2021-05-01
Est. Completion 2023-08-31
Phase NA

Sponsor

Q2i

4 total trials

What the Registry Record Tells You About NCT05017272

The ClinicalTrials.gov registry entry for NCT05017272 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 246 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,655-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (95% lower). The listed sponsor is Q2i, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Opioid Use Disorder appearing as the primary indexed condition, and to 1 intervention - of which Opioid Addiction Recovery Support Software Platform is the first listed.

NCT05017272 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT05017272 about?

NCT05017272 is a clinical study titled "Technology for MAT in Primary Care - Phase 2". With over 72,000 overdose deaths in 2017, of which 47,600 are attributable to opioid overdose, the opioid epidemic has become North America's most widespread behavioral public health problem. Medication-assisted treatment (MAT) for opioid use disorder (OUD) is highly efficacious. The Opioid Addictio...

What is the current status of trial NCT05017272?

This trial is currently completed. It is a NA study. The enrollment target is 246 participants. The study started on 2021-05-01. Estimated completion is 2023-08-31.

What conditions does trial NCT05017272 study?

This clinical trial studies the following conditions: Opioid Use Disorder.

What interventions are being tested in trial NCT05017272?

The interventions under investigation include: Opioid Addiction Recovery Support Software Platform (OTHER).

Who is sponsoring clinical trial NCT05017272?

This trial is sponsored by Q2i, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05017272 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Opioid Use Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.